ASX ANNOUNCEMENT Actinogen XanaMIA pivotal Alzheimer’s disease trial achieves database lock, confirming topline results now expected mid-November Sydney, 21 October 2026. Actinogen Medical ASX: ACW (“ACW” or “the Company”) is pleased to announce that following formal achievement of its...